Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 33,600 shares of the firm's stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $9.53, for a total value of $320,208.00. Following the transaction, the chief executive officer now directly owns 13,956,568 shares in the company, valued at $133,006,093.04. This trade represents a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.
David Zaccardelli also recently made the following trade(s):
- On Thursday, May 29th, David Zaccardelli sold 208,696 shares of Verona Pharma stock. The stock was sold at an average price of $9.33, for a total value of $1,947,133.68.
- On Wednesday, May 28th, David Zaccardelli sold 157,704 shares of Verona Pharma stock. The stock was sold at an average price of $9.30, for a total value of $1,466,647.20.
- On Tuesday, April 29th, David Zaccardelli sold 90,360 shares of Verona Pharma stock. The stock was sold at an average price of $8.98, for a total value of $811,432.80.
Verona Pharma Price Performance
VRNA stock traded up $0.71 during trading on Tuesday, hitting $84.81. The company had a trading volume of 1,838,843 shares, compared to its average volume of 1,318,074. The company has a fifty day moving average price of $65.98 and a two-hundred day moving average price of $57.49. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The company has a market cap of $6.88 billion, a P/E ratio of -44.17 and a beta of 0.20. Verona Pharma plc has a fifty-two week low of $11.79 and a fifty-two week high of $85.27.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million. Equities research analysts expect that Verona Pharma plc will post -1.95 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently weighed in on VRNA. Roth Capital set a $83.00 price target on Verona Pharma in a research note on Friday, February 28th. TD Cowen began coverage on Verona Pharma in a research note on Monday, April 28th. They issued a "buy" rating and a $100.00 price target on the stock. Canaccord Genuity Group lifted their price target on Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Cowen began coverage on Verona Pharma in a research report on Monday, April 28th. They set a "buy" rating for the company. Finally, HC Wainwright raised their price objective on Verona Pharma from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Monday. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $82.13.
Read Our Latest Stock Report on Verona Pharma
Hedge Funds Weigh In On Verona Pharma
Several large investors have recently made changes to their positions in VRNA. NBC Securities Inc. bought a new stake in Verona Pharma in the first quarter valued at about $34,000. Geneos Wealth Management Inc. increased its holdings in Verona Pharma by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after purchasing an additional 193 shares during the last quarter. Vermillion Wealth Management Inc. bought a new stake in Verona Pharma in the fourth quarter valued at about $46,000. Acadian Asset Management LLC bought a new stake in Verona Pharma in the first quarter valued at about $48,000. Finally, NewEdge Advisors LLC bought a new stake in Verona Pharma in the first quarter valued at about $58,000. Institutional investors and hedge funds own 85.88% of the company's stock.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
